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Chronic Hepatitis B — New Goals, New Treatment
Ching-Lung Lai, M.D., and Man-Fung Yuen, M.D.
The hepatitis B virus (HBV) causes chronic in-
fection in approximately 400 million people in 
the world. Most carriers of chronic HBV, including 
Asians, Africans, and a proportion of persons in 
Mediterranean countries, acquire the infection at 
birth or within the first 1 to 2 years after birth.1 
It is estimated that 50% of male carriers and 
14% of female carriers will eventually die of the 
complications of cirrhosis and hepatocellular car-
cinoma.2
The criteria and end points for the treatment 
of chronic HBV infection should be reevaluated 
in light of three important recent findings. First, 
more than 70% of patients with complications 
of cirrhosis and hepatocellular carcinoma are 
negative for the hepatitis B e antigen (HBeAg).3 
Therefore, although the disease may become qui-
escent in some patients after HBeAg seroconver-
sion, the disease can progress, and most dis-
ease-related deaths occur in these patients. Even 
with clearance of the hepatitis B surface antigen 
(HBsAg), there is no decrease in the risk of hep-
atocellular carcinoma if the HBsAg is lost in pa-
tients after the age of 50 years.4 
Second, an elevated HBV DNA level of more 
than 2000 IU per milliliter (104 copies per mil-
liliter) is a strong independent predictor of the 
risk of complications of cirrhosis and hepatocel-
lular carcinoma.5,6 Prolonged, effective suppres-
sion of HBV DNA has been shown to decrease the 
risk of the development of cirrhosis and hepato-
cellular carcinoma.7,8 
Finally, as is the case in chronic hepatitis C 
infection, patients with chronic HBV infection who 
have alanine aminotransferase levels that are 
near the upper limit of the normal range are at 
a significantly higher risk for complications of 
cirrhosis and hepatocellular carcinoma than pa-
tients with alanine aminotransferase levels that 
are less than half the upper limit of the normal 
range.3 The highest risk of complications of cir-
rhosis and hepatocellular carcinoma occurs in pa-
tients with alanine aminotransferase levels that 
are one to two times the upper limit of the nor-
mal range.
The implications for the treatment of chronic 
HBV infection are that, other than the tradition-
al end point of HBeAg seroconversion alone, a 
more important aim is the sustained suppression 
of HBV DNA to very low levels, preferably to be-
low the detection limit of sensitive polymerase-
chain-reaction (PCR) assays.1 The alanine amino-
transferase level should also ideally be lower than 
half the upper limit of the normal range.
The first licensed agent for the treatment of 
chronic HBV infection was the conventional form 
of interferon alfa, which acts mainly through 
immunomodulation and has the advantage of 
being given over a fixed period of time, although 
this is partly because of its often severe side ef-
fects. However, the majority of patients still have 
levels of HBV DNA that are detectable by means 
of PCR assays after treatment, and most studies 
show no decrease in the occurrence of hepato-
cellular carcinoma on long-term follow-up.9,10 
The short-term efficacy of pegylated interferon 
(peginterferon), licensed in 2005, is almost iden-
tical to that of conventional interferon. Data on 
its long-term effects on the development of cirrho-
sis and hepatocellular carcinoma have not yet been 
published.
Lamivudine, a nucleoside analogue, was licensed 
in 1998. Nucleoside and nucleotide analogues sup-
press HBV replication through inhibition of the 
reverse-transcriptase and DNA polymerase activi-
ties. During the past decade, four other nucleo-
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side and nucleotide analogues have been licensed: 
adefovir (in 2002), entecavir (in 2005), telbivudine 
(in 2006), and, most recently, tenofovir disoproxil 
fumarate (DF) (in 2008).
In this issue of the Journal, Marcellin et al.11 
report on two studies comparing the antiviral ef-
ficacy of tenofovir DF with that of adefovir dipiv-
oxil in both HBeAg-negative and HBeAg-positive 
patients; 18% of the HBeAg-negative patients had 
received lamivudine previously. At week 48, ten-
ofovir DF was superior to adefovir dipivoxil in 
achieving the primary end point, defined as the 
combination of an HBV DNA level of less than 
400 copies per milliliter (69 IU per milliliter) and 
histologic improvement (P<0.001). A total of 93% 
of the HBeAg-negative patients and 76% of the 
HBeAg-positive patients who received tenofovir DF 
(the intention-to-treat population) had an HBV 
DNA level of less than 400 copies per milliliter by 
week 48. The choice of this HBV DNA level as the 
primary end-point threshold was dictated by the 
detection limit of the sequencing assay used for 
resistance surveillance. However, the detection 
limit of the PCR assay used for quantification of 
HBV DNA in the studies was 169 copies per milli-
liter (29 IU per milliliter). This end-point thresh-
old for HBV DNA would have been a better 
choice, because lower levels of HBV DNA measure-
ment would allow earlier detection of viral re-
bound12 and because the modern treatment end 
points aim at suppressing HBV DNA to as low a 
level as possible.1
Two of the most encouraging aspects of ten-
ofovir DF in the studies reported by Marcellin et 
al. are its efficacy in patients with a lamivudine-
resistant virus and the absence of resistant mu-
tations up to week 48. A longer treatment period 
is of course required to determine the incidence 
of tenofovir DF resistance. The relative efficacy 
and resistance rates of the approved drugs are list-
ed in Table 1.
The most obvious niche for tenofovir DF is in 
Table 1. HBV DNA Suppression and Resistance Rates Associated with Different Therapeutic Agents.*
Variable 
Pegylated  
Interferon Lamivudine
Adefovir  
Dipivoxil Entecavir Telbivudine Tenofovir DF
percent of patients
HBeAg-positive patients
Undetectable HBV DNA by PCR† 
1 yr 25 36 21 67 60 76
2 yr NA NA 40 80 56 NA
3 yr NA NA 48 82 NA NA
Resistance
1 yr 0 24 0 <1 4 0
2 yr — 42 NA <1 25 NA
5 yr — 76 20 1 NA NA
HBeAg-negative patients
Undetectable HBV DNA by PCR† 
1 yr 63 72 63 90 88 93
2 yr NA NA 71 94 82 NA
3 yr NA NA 79 NA NA NA
Resistance 
1 yr 0 21 0 <1 3 0
2 yr — 35 3 <1 11 NA
5 yr — NA 29 1 NA NA
* Data are from Yuen et al.,13 Marcellin et al.,11,14 Hadziyannis et al.,15 Tenney et al.,16 and Liaw et al.17 HBeAg denotes hepatitis B e anti-
gen, HBV hepatitis B virus, NA not available, and PCR polymerase chain reaction.
† The lower limit of detection varied from 40 to less than 200 IU per milliliter (200 to <1000 copies per milliliter).
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the treatment of patients with lamivudine-resis-
tant HBV. Tenofovir DF is superior to adefovir 
dipivoxil and entecavir in these patients, and it 
has a much lower renal toxicity than adefovir 
dipivoxil.18 An even greater prospect is its poten-
tial use as a first-line drug in patients who have 
not received treatment; these patients compose 
the great majority of the population of persons 
with chronic HBV infection in the world. One of 
the besetting problems with nucleoside and nu-
cleotide analogues is the development of resis-
tance with long-term use. Early suppression of 
HBV DNA (e.g., to <40 IU per milliliter [200 cop-
ies per milliliter] by week 24) has proved to be 
associated with low rates of resistance develop-
ment.13 Although we must await further studies 
to determine the long-term resistance to tenofovir 
DF, it is encouraging to note that 86% of HBeAg-
negative patients and 50% of HBeAg-positive pa-
tients had HBV DNA levels that were less than 
400 copies per milliliter at week 24. The resis-
tance rate for adefovir dipivoxil after 5 years of 
treatment is 20% among HBeAg-positive patients 
and 29% among HBeAg-negative patients.14,15 It 
is to be expected that resistance to tenofovir DF 
would be lower because of its greater efficacy in 
viral suppression.
Finally, what is the possible future role of 
tenofovir DF in combination therapy? In HBeAg-
negative patients, long-term therapy with nucle-
oside and nucleotide analogues is the standard 
practice. However, in HBeAg-positive patients, 
most treatment guidelines suggest that therapy 
may be discontinued after a stable HBeAg sero-
conversion, preferably with levels of HBV DNA 
that are undetectable by means of PCR assays. 
Nevertheless, at least one study in HBeAg-positive 
patients shows that even with a relatively weak 
agent such as lamivudine, continuing drug treat-
ment after HBeAg seroconversion results in better 
sustained suppression of HBV DNA and fewer 
alanine aminotransferase flares than discontin-
uing the treatment.19 Long-term therapy in both 
HBeAg-positive and HBeAg-negative patients with 
sustained viral suppression will most likely be 
the trend in the future. The problem of resistance 
will become a major concern. Although most stud-
ies with combination therapy show no additive an-
tiviral effects, combination therapy has resulted 
in a reduction of resistance development. The 
ideal combination may be a nucleoside analogue 
such as lamivudine or telbivudine with a nucleo-
tide analogue such as adefovir dipivoxil or teno-
fovir DF; in this combination therapy, one group 
of agents will remain sensitive to the resistant mu-
tant viruses of the other group. However, if the 
long-term resistance to tenofovir DF turns out 
to be very low, similar to the 1.2% resistance rate 
after 5 years of treatment with entecavir among 
patients who have not received treatment previ-
ously,16 long-term monotherapy with tenofovir DF 
or entecavir is another possible option.
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